BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Jefferies Financial Group raised their FY2022 earnings per share estimates for shares of BioCryst Pharmaceuticals in a note issued to investors on Wednesday, November 7th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biotechnology company will earn $0.28 per share for the year, up from their previous estimate of $0.25. Jefferies Financial Group has a “Buy” rating and a $8.50 price target on the stock.

BCRX has been the topic of a number of other reports. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 15th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 12th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $9.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 7th. Bank of America raised shares of BioCryst Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, July 17th. Finally, BidaskClub raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $9.89.

Shares of BCRX opened at $7.70 on Friday. The company has a market capitalization of $875.66 million, a P/E ratio of -9.87 and a beta of 1.75. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 0.35. BioCryst Pharmaceuticals has a 1-year low of $4.25 and a 1-year high of $8.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The company had revenue of $1.45 million during the quarter, compared to analysts’ expectations of $2.53 million. BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 145.89%.

Several hedge funds have recently bought and sold shares of the business. American International Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 12.8% during the third quarter. American International Group Inc. now owns 72,390 shares of the biotechnology company’s stock worth $552,000 after acquiring an additional 8,236 shares in the last quarter. BlackRock Inc. increased its stake in shares of BioCryst Pharmaceuticals by 13.1% in the third quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after buying an additional 1,013,905 shares during the period. Bank of New York Mellon Corp increased its stake in shares of BioCryst Pharmaceuticals by 3.1% in the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock worth $3,211,000 after buying an additional 12,544 shares during the period. Janus Henderson Group PLC increased its stake in shares of BioCryst Pharmaceuticals by 10.4% in the third quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock worth $93,469,000 after buying an additional 1,153,978 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of BioCryst Pharmaceuticals by 10.9% in the third quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock worth $29,376,000 after buying an additional 378,565 shares during the period. 79.82% of the stock is currently owned by hedge funds and other institutional investors.

In other BioCryst Pharmaceuticals news, VP Lynne Powell sold 5,280 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $8.15, for a total transaction of $43,032.00. Following the transaction, the vice president now directly owns 8,905 shares of the company’s stock, valued at $72,575.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas R. Staab II sold 9,850 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total transaction of $71,314.00. Following the transaction, the insider now directly owns 140,633 shares in the company, valued at $1,018,182.92. The disclosure for this sale can be found here. Insiders have sold 45,182 shares of company stock worth $352,176 over the last three months. Insiders own 4.50% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.